Jafron Reconciled Depreciation from 2010 to 2025
| 300529 Stock | 25.73 0.54 2.06% |
Reconciled Depreciation | First Reported 2010-12-31 | Previous Quarter 109 M | Current Value 114.5 M | Quarterly Volatility 36.2 M |
Check Jafron Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jafron Biomedical's main balance sheet or income statement drivers, such as Interest Expense of 65.6 M, Selling General Administrative of 312.9 M or Total Revenue of 1.2 B, as well as many indicators such as . Jafron financial statements analysis is a perfect complement when working with Jafron Biomedical Valuation or Volatility modules.
Jafron | Reconciled Depreciation |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Jafron Stock
Jafron Biomedical financial ratios help investors to determine whether Jafron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jafron with respect to the benefits of owning Jafron Biomedical security.